[go: up one dir, main page]

JPH11500119A - インターロイキン１２を用いる脈管形成の阻害 - Google Patents

インターロイキン１２を用いる脈管形成の阻害

Info

Publication number
JPH11500119A
JPH11500119A JP8524631A JP52463196A JPH11500119A JP H11500119 A JPH11500119 A JP H11500119A JP 8524631 A JP8524631 A JP 8524631A JP 52463196 A JP52463196 A JP 52463196A JP H11500119 A JPH11500119 A JP H11500119A
Authority
JP
Japan
Prior art keywords
angiogenesis
treatment
disease
mice
interleukin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP8524631A
Other languages
English (en)
Japanese (ja)
Inventor
フォークマン，モーゼス・ユダ
トゥルーイット，ゲーリー・アーサー
フースト，エミーレ・ユーヘネ
Original Assignee
エフ・ホフマン−ラ ロシュ アーゲー
ザ・チルドレンズ・メディカル・センター・コーポレーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エフ・ホフマン−ラ ロシュ アーゲー, ザ・チルドレンズ・メディカル・センター・コーポレーション filed Critical エフ・ホフマン−ラ ロシュ アーゲー
Publication of JPH11500119A publication Critical patent/JPH11500119A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP8524631A 1995-02-16 1996-02-07 インターロイキン１２を用いる脈管形成の阻害 Pending JPH11500119A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38938295A 1995-02-16 1995-02-16
US389,382 1995-02-16
PCT/EP1996/000507 WO1996025171A1 (en) 1995-02-16 1996-02-07 Inhibition of angiogenesis using interleukin-12

Publications (1)

Publication Number Publication Date
JPH11500119A true JPH11500119A (ja) 1999-01-06

Family

ID=23538033

Family Applications (1)

Application Number Title Priority Date Filing Date
JP8524631A Pending JPH11500119A (ja) 1995-02-16 1996-02-07 インターロイキン１２を用いる脈管形成の阻害

Country Status (8)

Country Link
EP (1) EP0809511A1 (sv)
JP (1) JPH11500119A (sv)
AU (1) AU4788396A (sv)
BR (1) BR9607427A (sv)
CA (1) CA2212370A1 (sv)
FI (1) FI973356A0 (sv)
TR (1) TR199700801T1 (sv)
WO (1) WO1996025171A1 (sv)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004060373A1 (ja) * 2002-12-27 2004-07-22 Santen Pharmaceutical Co., Ltd. 滲出型加齢黄斑変性治療剤

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998022129A1 (fr) * 1996-11-22 1998-05-28 Toray Industries, Inc. Agent therapeutique pour maladies ophtalmiques
US5981508A (en) 1997-01-29 1999-11-09 Vanderbilt University Facilitation of repair of neural injury with CM101/GBS toxin
US5858991A (en) * 1997-01-29 1999-01-12 Vanderbilt University Facilitation of wound healing with CM101/GBS toxin
US6028060A (en) 1997-01-29 2000-02-22 Vanderbilt University Treatment of chronic inflammatory diseases with CM101/GBS toxin
US6670337B1 (en) 1998-01-29 2003-12-30 Yeda Reaearch And Development Co., Ltd. Facilitation of wound healing with CM101/GBS toxin
US6660258B1 (en) 1997-05-09 2003-12-09 Pharma Pacific Pty Ltd Oromucosal cytokine compositions and uses thereof
EP0986393B1 (en) * 1997-05-27 2004-03-24 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES The use of a nitroxide or a prodrug thereof in the prophylactic and therapeutic treatment of cancer
JP2001521906A (ja) * 1997-11-03 2001-11-13 ザ・ウイスター・インステイテユート・オブ・アナトミー・アンド・バイオロジー 血管新生を阻害し、癌を処置するための方法及び組成物
AU2002303168B2 (en) 2001-03-29 2005-10-06 Schering Corporation Aryl oxime-piperazines useful as ccr5 antagonists
BRPI0408704A (pt) 2003-03-24 2006-03-07 Hoffmann La Roche benzil-piridazinonas como inibidores de transcriptase reversa
BRPI0617720A2 (pt) 2005-10-19 2011-08-02 Hoffmann La Roche compostos inibidores de nnrt de fenil-acetamida, usos dos referidos compostos e composição farmacêutica que os contém
RU2451676C2 (ru) 2006-08-16 2012-05-27 Ф.Хоффманн-Ля Рош Аг Ненуклеозидные ингибиторы обратной транскриптазы
CA2671478C (en) 2006-12-13 2015-02-17 F. Hoffmann-La Roche Ag Non-nucleoside reverse transcriptase inhibitors
CN109789187A (zh) * 2016-07-18 2019-05-21 创新疗法医药有限公司 Il-12作为替代免疫治疗剂的用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2106368A1 (en) * 1992-01-16 1993-07-17 Theodore E. Maione Methods and compositions for treatment of angiogenic disease
JPH06157344A (ja) * 1992-02-07 1994-06-03 Childrens Medical Center Corp:The 血管新生阻害のための医薬製剤及び血管新生阻害方法

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004060373A1 (ja) * 2002-12-27 2004-07-22 Santen Pharmaceutical Co., Ltd. 滲出型加齢黄斑変性治療剤

Also Published As

Publication number Publication date
WO1996025171A1 (en) 1996-08-22
BR9607427A (pt) 1998-06-23
TR199700801T1 (xx) 1998-03-21
FI973356L (sv) 1997-08-15
AU4788396A (en) 1996-09-04
MX9706188A (es) 1997-11-29
FI973356A7 (sv) 1997-08-15
CA2212370A1 (en) 1996-08-22
EP0809511A1 (en) 1997-12-03
FI973356A0 (sv) 1997-08-15

Similar Documents

Publication Publication Date Title
JP4065373B2 (ja) サリドマイドを有効成分とする医薬品製剤
JPH11500119A (ja) インターロイキン１２を用いる脈管形成の阻害
Ezra Neovasculogenesis. Triggering factors and possible mechanisms
AU640954B2 (en) Anti-tumor preparation comprising interleukin-2 and histamine, analogs thereof or H2-receptor agonists
EP0579830A1 (en) Therapeutic agent for corneal lesion
JP6494594B2 (ja) 樹状細胞を含有する医薬およびその製造方法
ES2207858T3 (es) Composicion farmaceutica activa para reducir la produccion de proteina mcp-1".
JP2016516071A (ja) 瘢痕形成を軽減するためのｓｄｆ−１の使用
PT99265B (pt) Processo para a preparacao de composicoes farmaceuticas contendo interferon humano e metodo de tratamento de doencas proliferativas celulares
KR20190039145A (ko) 대체 면역요법으로서의 il-12의 용도
RU2730998C2 (ru) Композиции форболовых эфиров и способы их применения для лечения или уменьшения продолжительности цитопении
TWI310312B (en) Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of macular degeneration
JPH10502371A (ja) リンホトキシンを用いる癌処置法
EP0287633A1 (en) COMBINATIONS OF TUMOR NECROSIS FACTORS AND ANTI-INFLAMMATORY AGENTS FOR THE TREATMENT OF MALIGNANT AND NON-MALIGNANT DISEASES.
MXPA97006188A (en) Inhibition of angiogenesis using interleucin
JPH0747545B2 (ja) 創傷治癒及び修復の修復段階を促進し、かつ感染した創傷及び糖尿病哺乳類の創傷の治癒を促進するためのｉｌ−４の用途
US6191158B1 (en) Pharmaceutical composition active in reducing production of MCP-1 protein
EP1722811B1 (en) Use of hepatocyte growth factor for promoting induction of vascular differentiation
JPH02121923A (ja) ４―キノリンカルボン酸誘導体とインターロイキン―２の同時投与による哺乳動物のガン治療
CN1189102A (zh) 白细胞介素－12对血管生成的抑制作用
WO1989001778A1 (en) Agents for prophylaxis and treatment of thrombopenia
WO2001028573A2 (en) Monocyte conditioned medium for cancer treatment
WO1991016916A1 (en) Antineoplastic agent
Novogrodsky et al. Antitumor properties of mononuclear cells activated by combined treatment with oxidizing mitogens and interleukin-2: basic and clinical studies
WO1997021446A1 (fr) Composition pharmaceutique pour la protection des cellules souches hematopoietiques, et applications